<DOC>
	<DOCNO>NCT00869518</DOCNO>
	<brief_summary>DESIGN : This single center , double-blinded , randomized phase II study conduct assess efficacy rifabutin base regimen eliminate S. aureus colonization HIV infected individual . Individuals must HIV infection skin skin structure infection ( SSSI ) prior 6 month eligible screening . Prior enrollment , subject culture evidence S. aureus colonization . Individuals culture positive ≥ one body site eligible enrollment . Subjects meet inclusion exclusion criterion consent participate study randomize seven day rifabutin plus trimethoprim-sulfamethoxazole ( TMP-SMX ) TMP-SMX alone . Following completion treatment subject screen seven day , 30 day , 60 day post-treatment colonization multiple body-sites . Subjects also actively follow evidence SSSI . SUBJECT PARTICIPATION DURATION : 12 week SAMPLE SIZE : 88 total subject POPULATION : 200 HIV infected individual receive care San Francisco General Hospital HIV clinic ( Ward 86 ) history SSSI prior 6 month screen S. aureus colonization . DESCRIPTION OF AGENT OR INTERVENTION : This double-blind trial compare rifabutin plus TMP-SMX versus placebo plus TMP-SMX . Placebo administer dose 300 mg p.o . daily equivalent dose depend co-administration drug may adjust serum level rifabutin . TMP-SMX administer dose trimethoprim 160 mg sulfamethoxazole 800 mg p.o . twice daily adjust per CrCl . Study drug provide study administer 7 day .</brief_summary>
	<brief_title>Rifabutin Based Therapy Eradication Staphylococcus Aureus Colonization HIV Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . HIV infection report subject 's physician 3 . Physicianreported SSSI within prior 6 month . 4 . S. aureus colonization ≥ 1 body site define positive culture S. aureus minimum one five culture take preenrollment screening . 5 . Subjects ( legally acceptable representative ) must sign informed consent documentation indicate understand purpose procedure require study , willing participate study 1 . Female subject pregnant lactating . 2 . Known suspected hypersensitivity rifabutin , rifamycin class antimicrobial , TMPSMX another sulfa base medication . 3 . Known suspected condition concurrent treatment would contraindicate prescribe rifabutin TMPSMX . 4 . Receipt antistaphylococcal antimicrobial within 14 day prior administration study drug ( TMPSMX , clindamycin , macrolide , tetracycline , rifamycin , fluoroquinolone , vancomycin , linezolid , daptomycin , penicillin , carbapenem , cephalosporin ) . 5 . Diagnosis active SSSI sign symptom S. aureus infection time study enrollment 6 . Physicianreported diagnosis active untreated latent mycobacterial infection 7 . CrCl &lt; 30 ml/min determine CockcroftGault Method use serum creatinine value obtain within last 6 month . 8 . No serum creatinine value available subject SFGH clinical laboratory system ( LCR ) within 6 month prior enrollment . 9 . Physicianreported diagnosis endstage liver disease 10 . Physicianreported diagnosis uveitis past time enrollment 11 . Concomitant use medication unknown pharmacokinetic interaction rifabutin contraindicate rifabutin ( unboosted indinavir , unboosted saquinavir , delavirdine , atovaquone , azithromycin , Bacillus Calmette Guerin [ recent administration bladder cancer treatment ] , dapsone , dasatinib , erlotininb , ethinyl estradiol , fluconazole , imatinab , itinotecan , itraconazole , ixabepilone , lapatinib , levonorgestrel , mestranol , nilotininb , norelgestromin , norethindrone , posaconazole , ranolazine , sirolimus , sunitinib , tacrolimus , temsirolimus , trimetrexate , voriconazole , warfarin ) 12 . Colonizing S. aureus isolate resistant TMPSMX 13 . Colonizing S. aureus isolate resistant rifampin ( rifampin resistance serve surrogate rifabutin resistance initial screening ) 14 . Subjects unlikely able comply mandate study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>colonization</keyword>
	<keyword>eradication</keyword>
	<keyword>HIV</keyword>
	<keyword>rifabutin</keyword>
</DOC>